65 unknown. 65 Phase 3, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 65 | Unknown 65 |
| Phase 2 | 11 | Unknown 11 |
Follow Hepatitis: new trials by email Literature Review of Hepatitis trials Research Report on Hepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder Glecaprevir/pibrentasvir, Placebo - PTSD | Phase 2 / Phase 3 | Unknown | White River Junction Veterans Affairs Medical Center | 92 | 2023-12-18 | 2025-04-24 |
| To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL, HAVRIX 720 Junior 0.5 mL - Hepatitis A, Hep A | Phase 3 | Unknown | Boryung Biopharma Co., Ltd. | 106 | 2022-12-01 | 2022-11-14 |
| Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial N acetyl cysteine - Tuberculosis, Drug Induced Liver Injury | Phase 2 / Phase 3 | Unknown | Mahidol University | 82 | 2022-09-09 | 2023-02-22 |
| Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV Peginterferon Lambda-1a - Hepatitis Delta Virus | Phase 3 | Unknown | Eiger BioPharmaceuticals | 150 | 2021-12-21 | 2023-08-25 |
| Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet, Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate - Chronic Hepatitis b | Phase 3 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 900 | 2020-09-01 | 2020-09-10 |
| Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients Sofosbuvir , daclatasvir, Placebos - Chronic Hepatitis c | Phase 3 | Unknown | Assiut University | 50 | 2019-09-01 | 2019-09-12 |
| Micro-elimination of Hepatitis C Virus Infection in Uremics Epclusa - Hepatitis C | Phase 3 | Unknown | Kaohsiung Medical University Chung-Ho Memorial Hospital | 135 | 2019-05-13 | 2020-07-10 |
| SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C SH229 tablets, Daclatasvir dihydrochloride - Hepatitis C, Chronic | Phase 2 / Phase 3 | Unknown | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 440 | 2019-03-29 | 2019-08-28 |
| Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity Ribavirin, Tenofovir - Hepatitis B, Chronic | Phase 3 | Unknown | Ottawa Hospital Research Institute | 24 | 2019-01-10 | 2021-09-14 |
| Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients Seraprevir, Sofosbuvir - Hepatitis C Virus Infection | Phase 3 | Unknown | Ginkgopharma CO., LTD | 206 | 2018-10-17 | 2019-06-28 |
| Transplantation Using Hepatitis C Positive Donors, A Safety Trial Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet, Ezetimibe 10Mg Oral Tablet, Ex Vivo Lung Perfusion - Lung Transplant Infection, Heart Transplant Infection | Phase 3 | Unknown | Jordan Feld | 40 | 2018-08-06 | 2019-07-12 |
| PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders Sofosbuvir and Ledipasvir - HCV Infection, Beta Thalassemia Major | Phase 3 | Unknown | Ain Shams University | 24 | 2018-06-11 | 2023-03-06 |
| Impact of a Fourth Hexavalent Vaccine After Hematopoietic Stem Cell Transplantation 4th dose of hexavalent vaccine 1 month after the 3rd dose - Haemopoietic Stem Cell Transplantation, Allograft | Phase 3 | Unknown | University Hospital, Grenoble | 200 | 2018-05-01 | 2018-06-06 |
| Fecal Microbial Transplantation in Severe Alcoholic Hepatitis Fecal microbial transplantation - Alcoholic Hepatitis | Phase 3 | Unknown | F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica | 50 | 2018-04-01 | 2022-08-03 |
| HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102 GC1102 80,000 IU, GC1102 100,000 IU, I.V HBIG - Hepatitis B Infection | Phase 2 / Phase 3 | Unknown | Green Cross Corporation | 186 | 2018-03-29 | 2020-01-30 |
| Effect of Direct-acting Antiviral Drugs on Erectile Function Sofosbuvir and Daklatasuvir - Hepatitis C | Phase 3 | Unknown | Sherief Abd-Elsalam | 105 | 2018-01-01 | 2020-10-22 |
| Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b Elbasvir/ Grazoprevir 50/100 mg fixed dose combination - Chronic Hepatitis C Genotype 1B, Metabolic Syndrome | Phase 3 | Unknown | Institute Of Cardiology & Internal Diseases, Kazakhstan | 60 | 2017-10-01 | 2017-08-07 |
| Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial Administration of DAA-based treatment - Hepatocellular Carcinoma, Hepatitis C, Chronic | Phase 3 | Unknown | Ain Shams University | 80 | 2017-10-01 | 2018-06-11 |
| Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients Grazoprevir 100 mg/d 8 weeks, Elbasvir 50 mg/d 8 weeks, Grazoprevir 100 mg/d 12 weeks - Hepatitis C, HIV | Phase 3 | Unknown | Fundacion Clinic per a la Recerca Biomédica | 62 | 2017-04-28 | 2019-02-15 |
| Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents 12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg), 8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg) - Hepatitis C Virus Infection, Response to Therapy of | Phase 3 | Unknown | Egyptian Liver Hospital | 80 | 2017-04-15 | 2018-05-24 |
Showing 20 of 65. Sign in to see all of them.
Hepatitis C (23) · Hepatitis B, Chronic (15) · Hepatitis C, Chronic (14) · Hepatitis B (8) · HIV Infections (5) · Hepatitis, Alcoholic (4) · Hepatitis A (3) · Carcinoma, Hepatocellular (2) · Chemical and Drug Induced Liver Injury (1) · Chickenpox (1) · Cholangiocarcinoma (1) · Drug Misuse (1) · Fatty Liver (1) · Fibrosis (1)
Digestive System Diseases (65) · Liver Diseases (65) · Infections (59) · Virus Diseases (58) · Hepatitis, Viral, Human (57) · Blood-Borne Infections (54) · Communicable Diseases (54) · RNA Virus Infections (39) · Flaviviridae Infections (33) · Pathological Conditions, Signs and Symptoms (32) · Pathologic Processes (31) · Chronic Disease (29) · Disease Attributes (29) · Hepatitis, Chronic (28)
Ribavirin (14) · peginterferon alfa-2a (9) · Sofosbuvir (8) · Tenofovir (5) · elbasvir (3) · grazoprevir (3) · Acetylcysteine (2) · Metformin (2) · Pentoxifylline (2) · daclatasvir (2) · entecavir (2) · ledipasvir (2) · peginterferon alfa-2b (2) · ravidasvir (2) · ((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl (1)
Ain Shams University (2) · IRCCS San Raffaele (2) · Kaohsiung Veterans General Hospital. (2) · Mahidol University (2) · Tel-Aviv Sourasky Medical Center (2) · ANRS, Emerging Infectious Diseases (1) · Aalborg University Hospital (1) · Assiut University (1) · BioGeneric Pharma (1) · Boryung Biopharma Co., Ltd. (1) · Cairo University (1) · Chiang Mai University (1) · Chong Kun Dang Pharmaceutical (1) · Clinical Research Organization, Dhaka, Bangladesh (1) · Drugs for Neglected Diseases (1)
Egypt (9) · China (8) · South Korea (7) · Thailand (5) · France (4) · Italy (4) · Taiwan (4) · Canada (3) · Brazil (2) · Germany (2) · Israel (2) · Spain (2) · United States (2) · Australia (1) · Bangladesh (1)
Adriano Lazzarin, MD (2) · Amanda Quevedo, Sub Coord (1) · Bita Behnava, MD (1) · Bradley V Watts, MD, MPH (1) · Byung Seok Lee, M.D., Ph.D. (1) · Curtis L Cooper, MD (1) · Daiana V. Gomes, AssitSocial (1) · Dong Joon Kim, M.D., Ph.D. (1) · Gamal Esmat, M.D. (1) · Gamal Esmat, MD (1) · Gamal Shiha, MD (1)
PMID 19811343, PMID 22170794, PMID 23109014, PMID 24265819, PMID 24431895, PMID 25469044, PMID 26860769, PMID 28404133, PMID 28935432, PMID 29682590, PMID 29998882, PMID 30133478, PMID 30448598, PMID 31711528, PMID 32245397, PMID 32355123, PMID 32389183, PMID 33303567, PMID 33493393, PMID 33865507, PMID 34186262, PMID 34307188, PMID 34807763, PMID 35080256, PMID 35149125, PMID 35867702, PMID 36586101, PMID 37856013, PMID 38046041, PMID 38473248, PMID 39662593, PMID 39663120, PMID 40665748, PMID 41144397, PMID 41335575, PMID 41366186
2015 (1)